GNG: Improving access to evidence to support countries decision making on vaccines.
Published: October 2025.
https://www.nitag-resource.org/compendium
WHO: Last Ebola patient in Democratic Republic of the Congo discharged.
Published: October 19, 2025.
A surprise bonus from COVID-19 vaccines: bolstering cancer treatment.
Patients who got shots of mRNA before starting a type of cancer immunotherapy lived much longer. The innovative messenger RNA (mRNA) vaccines that thwarted the ravages of COVID-19 may also help fight tumors in cancer patients, according to a new analysis of medical records and studies in mice. People with cancer who coincidentally received the mRNA shots before starting drugs designed to unleash the immune system against tumors lived significantly longer than those who didn’t get vaccinated, a research team announced yesterday at the European Society for Medical Oncology Congress in Berlin.
Published: October 23, 2025.
https://www.science.org/content/article/surprise-bonus-covid-19-vaccines-bolstering-cancer-treatment
Nepal reports the most Japanese encephalitis cases in years.
The Nepal Ministry of Health and Population report 133 Japanese encephalitis (JE) cases in the country since the summer, including 31 deaths. Both deaths and the number of infections is at their highest levels in recent years, health officials say.
Published: October 17, 2025.
https://outbreaknewstoday.substack.com/p/nepal-reports-the-most-japanese-encephalitis
CEPI: Serum Institute of India and CEPI supercharge pandemic response preparedness targeting H5N1.
CEPI is collaborating with the world’s largest vaccine manufacturer, Pune-based Serum Institute of India (SII) Pvt. Ltd., part of Cyrus Poonawalla Group, to boost pandemic response preparedness using a baculovirus vaccine platform to target H5N1 bird flu as a prototype for a potential Disease X—an as-yet-unknown pathogen with pandemic potential.
Published: October 13, 2025.
PAHO highlights 31 years without polio in the Americas and calls to strengthen vaccination efforts.
On World Polio Day (October 24), the Pan American Health Organization (PAHO) celebrates over three decades without wild poliovirus cases in the Americas. PAHO continues to highlight the importance of strengthening vaccination coverage to prevent a possible resurgence of this preventable disease.
Published: October 23, 2025.
Resurgence of Zoonotic H5N1 Avian Influenza in Cambodia: Findings from National and International One Health Surveillance Efforts.
“Resurgence of Zoonotic Highly Pathogenic Avian Influenza A(H5N1) Virus in Cambodia” (DOI: 10.1056/NEJMc2504302) details sixteen laboratory-confirmed human infections detected between February 2023 and August 2024, primarily among children and adolescents exposed to infected poultry.
Published: October 23, 2025.
https://www.pasteur-kh.org/2025/10/23/nejm-article/
Big increase in DENV-3 Dengue serotype reported in Santa Catarina, Brazil.
Santa Catarina state is facing a significant increase in cases of the DENV-3 dengue serotype this year. DENV-3 can cause symptoms similar to those of other serotypes, but it has the potential to lead to severe dengue if exposed to a different serotype later. Infections with DENV-3 are also associated with immune enhancement phenomena that can worsen symptoms if exposed to other serotypes in the future.
Published: October 27, 2025.
https://outbreaknewstoday.substack.com/p/big-increase-in-denv-3-dengue-serotype
Brazil: Chikungunya exceeds 10,000 confirmed cases in Cuiabá, Mato Grosso state in 2025.
According to the State Health Department’s (SES) Epidemiological Bulletin, there have been 10,978 confirmed cases in Cuiabá in 2025, with an incidence of 1,240.7 cases per 100,000 inhabitants. In addition, 27 chikungunya deaths have also been reported.
Published: October 24, 2025.
https://outbreaknewstoday.substack.com/p/brazil-chikungunya-exceeds-10000
Zambia Launches Malaria Vaccine to Protect Over Half Million Children.
The Ministry of Health also presented the Costed Primary Health Care (PHC) Strategy 2025–2031 and its Operational Plan (2025–2026).
Published: October 28, 2025.
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization.
Findings Reinforce QDENGA’s Long-Term Safety Profile and Two-Dose Vaccination Schedule. QDENGA is the Longest-Studied Dengue Vaccine and the Only Approved for Use Regardless of Prior Disease Exposure. Takeda is Expanding Global Access to QDENGA in Partnership with National Immunization Programs, Private Payors and Public Health Coalitions, with 18.6 million Doses Distributed in 11 Endemic Countries.
Published: November 3, 2025.
https://www.takeda.com/newsroom/newsreleases/2025/dengue-vaccine/
International collaborative effort to understand dengue and Zika.
The Dengue and Zika Immunology and Genomics Multi-Country Network (DeZi) is led by Imperial and received £5.65 million core funding from a Wellcome Trust Infectious Disease Award. This was supplemented by £600 thousand funding from Temasek and £600 thousand contribution from Singapore National Environment Agency’s Environmental Health Institute through UNITEDengue.
Published: November 4, 2025.
https://www.imperial.ac.uk/news/269973/international-collaborative-effort-understand-dengue-zika/
Gavi and partners commence design of RSV maternal vaccine programme.
Gavi, the Vaccine Alliance (Gavi), in collaboration with global health partners, has commenced the design phase of a new maternal vaccine programme targeting respiratory syncytial virus (RSV) burden in lower-income countries. This milestone, which coincides with RSV Awareness Week 2025, is a critical step towards protecting the most at-risk newborns and infants around the world from one of the leading causes of infant respiratory illness and hospitalisation.
Published: November 5, 2025.
Diphtheria case reported at Swiss asylum centre.
There has been an outbreak of the infectious disease diphtheria at the federal asylum centre in Embrach, canton Zurich. One person is in hospital.
Published: November 4, 2025.
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate.
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive results of its Phase 1 clinical trial investigating the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV).
Published: November 4, 2025.
How nasal vaccines could reduce the spread of disease.
That’s why scientists in the NOSEVAC project, led by the European Vaccine Initiative (EVI), are exploring ways of giving more vaccines through the nose. It would also be relatively painless, potentially improving vaccine uptake – at least among people with a fear of needles.
Published: October 23, 2025.
https://www.vaccinestoday.eu/stories/how-nasal-vaccines-could-reduce-the-spread-of-disease/.
Papua New Guinea strengthens immunisation following detection of vaccine-derived poliovirus. P
apua New Guinea (PNG) is responding to a new outbreak of circulating vaccine-derived poliovirus type 2 (cVDPV2), which was detected earlier this year in environmental samples and in healthy children from Lae City, Morobe Province. The outbreak marks the first detection of cVDPV2 since the country’s last circulating vaccine-derived poliovirus type 1 (cVDPV1) outbreak in 2018.
Published: November 6, 2025.
WHO voices concerns about equitable access to novel TB vaccines.
A new report from the World Health Organization (WHO) is calling for bold steps to ensure equitable access to future tuberculosis (TB) vaccines. As of September 2025, there are 16 candidate vaccines in clinical development, with 6 in phase 3 trials, and high-burden countries are starting to prepare for the rollout of a TB vaccine in coming years.
Published: November 6, 2025.
https://www.cidrap.umn.edu/tuberculosis/who-voices-concerns-about-equitable-access-novel-tb-vaccines
Seasonal surveillance of chikungunya virus disease in the EU/EEA, weekly report.
Since the beginning of 2025 and as of 5 November 2025, two countries in Europe have reported cases of chikungunya virus disease: France (776) and Italy (374). In the past week, France has reported eight new locally acquired1 cases of chikungunya virus disease. The cumulative number of locally acquired cases in France has reached 776, distributed across 77 clusters. Italy reported four new locally acquired cases of chikungunya virus disease. The cumulative number of locally acquired cases in Italy is 374, distributed across six clusters. Three clusters are currently active.
Published: November 5, 2025.
CEPI: Rift Valley Fever. Rift Valley fever is a disease whose epidemic potential lies in the intersection of global climate, trade and health security.
CEPI invests in a range of research programs aiming to address the threat, including a vaccine for humans.
PAHO calls for regional action after the loss of measles elimination status in the Americas.
As of November 7, 2025, 12,596 confirmed cases of measles have been reported in ten countries (approximately 95% of the region’s cases are concentrated in Canada, Mexico, and the United States), representing a 30-fold increase compared to 2024. In addition, 28 deaths have been recorded: 23 in Mexico, three in the United States, and two in Canada.
Published: November 10, 2025.
Should Florida Authorize a Second-Generation Dengue Vaccine.
As of November 11, 2025, the PAHO has confirmed more than 4.1 million dengue cases and 2,041 associated deaths. And in the United States, the U.S. CDC reported in late September 2025 that 2,560 locally acquired dengue cases had been documented across four jurisdictions this year. Traditionally, Miami-Dade County, Florida, has reported the most local dengue cases. However, during 2025, Brevard County (35) has surpassed Miami-Dade (16), Given the 180-mile distance along Florida’s east coast between these counties, there could be many undetected cases of dengue. Since the CDC’s vaccine committee appears not to be taking action to approve QDENGA in 2025, should Joseph A. Ladapo, MD, PhD, Florida’s Surgeon General, pave his own path and approve QDENGA? Ladapo has already provided distinct guidance regarding COVID-19 and measles vaccinations this year. Don Hackett, VBT’s publisher, asks…. as winter vacations are being planned for dengue-outbreak destinations in the Americas, isn’t it good public health policy to ensure that international travelers have an option in 2025 to protect themselves against this serious disease?
Published: November 11, 2025.
WHO: Ethiopia confirms first outbreak of Marburg virus disease.
Ethiopia’s Ministry of Health has confirmed an outbreak of Marburg virus disease in the South Ethiopia Region, the first of its kind in the country, following laboratory testing of samples from a cluster of suspected cases of viral hemorrhagic fever.
Published: November 14, 2025.
The First Known Human Case of H5N5 Bird Flu (in the US), What We Know So Far.
In early November 2025, public health authorities in Washington state confirmed what appears to be the first ever human infection by the H5N5 strain of avian influenza. Further laboratory testing identified the virus as H5N5 — a subtype previously seen in animals but never documented in humans. The confirmed case involves an older adult with significant underlying health issues. According to state officials, the patient developed high fever, confusion, and respiratory distress. The individual remains hospitalized, and authorities are closely monitoring health workers and others who have contact though so far, no additional infections have been identified.
Published: November 17, 2025.
https://seasia.co/2025/11/17/the-first-known-human-case-of-h5n5-bird-flu-what-we-know-so-far.
